112233-74-6

Basic information

• Product Name: N2-ACETYL-O6-(DIPHENYLCARBAMOYL)GUANINE
• Synonyms: N2-ACETYL-O6-(DIPHENYLCARBAMOYL)GUANINE;N2-acetyl-O6-(diphenylcarbamoyl)guanin;N2-ACETYL-O6-(DIPHENYLCARBAMOYL)GUANINE(WXG00805)
• CAS NO: 112233-74-6
• Molecular Formula: C₂₀H₁₆N₆O₃
• Molecular Weight: 388.38
• Mol File: 112233-74-6.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• Density: 1.41±0.1 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer, Under inert atmosphere
• Solubility: DMSO (Slightly), Ethyl Acetate (Slightly)
• PKA: 6.13±0.40(Predicted)
• CAS DataBase Reference: N2-ACETYL-O6-(DIPHENYLCARBAMOYL)GUANINE(CAS DataBase Reference)
• NIST Chemistry Reference: N2-ACETYL-O6-(DIPHENYLCARBAMOYL)GUANINE(112233-74-6)
• EPA Substance Registry System: N2-ACETYL-O6-(DIPHENYLCARBAMOYL)GUANINE(112233-74-6)

Safety Data

• Hazardous Substances Data: 112233-74-6(Hazardous Substances Data)

Usage

Uses

N2-Acetyl-O6-diphenylcarbamoylguanine is a reactant in the synthesis of 1'',2''-oxetane-nucleosides bearing 2''-C-Me substituents with anti-HCV activity.

Upstream product

• 83-01-2 diphenylcarbamic chloride 
• 73-40-5 2-amino-1,9-dihydro-6H-purin-6-one 
• 108-24-7 acetic anhydride 
• 19962-37-9 N-(6-oxo-6,9-dihydro-1H-purin-2-yl)acetamide 
• 3056-33-5 2,9-diacetylguanine 

Downstream Products

• 112233-75-7 2-(acetylamino)-6-(diphenylcarbamoyloxy)-9-(β-D-tri-O-acetylribofuranosyl)-9H-purine 
• 118-00-3 G 
• 223470-82-4 2',3',5'-tri-O-(4-toluoyl)-N²-acetyl-O⁶-diphenylcarbamoylguanosine-3',4',5',5-d4 
• 238096-60-1 <1',2',3',4',5'-13C5>-2',3',5'-tri-O-(4-toluoyl)-N²-acetyl-O⁶-diphenylcarbamoylguanosine 
• 406215-20-1 Diphenyl-carbamic acid 2-acetylamino-9-({benzyl-[2-((1S,2S,6R,7R)-3,5-dioxo-4-aza-tricyclo[5.2.1.0^2,6]dec-8-en-4-yl)-ethyl]-carbamoyl}-methyl)-9H-purin-6-yl ester 
• 406215-24-5 Diphenyl-carbamic acid 2-acetylamino-9-({[2-((1R,2R,6S,7S)-3,5-dioxo-4-aza-tricyclo[5.2.1.0^2,6]dec-8-en-4-yl)-ethyl]-naphthalen-2-ylmethyl-carbamoyl}-methyl)-9H-purin-6-yl ester 
• 93905-75-0 9-n-butylguanine 
• 14937-72-5 9-benzylguanine 
• 181868-46-2 (1'R,4'S)-1'-(2-acetamido-6-(N,N-diphenyl)carbamoyloxypurin-9-yl)-4'-methoxycarbonyl-cyclopent-2'-ene 
• 288866-31-9 (1'R,4'S)-1'-(2-acetamido-6-(N,N-diphenyl)carbamoyloxypurin-9-yl)-4'-phenylsulfonyl(nitro)methyl-cyclopent-2'-ene 
• 1276694-50-8 C₃₈H₅₂N₆O₃ 
• 390824-35-8 N²-acetyl-9-(2',3',5'-tri-O-acetyl-β-L-ribofuranosyl)-6-O-diphenylcarbamoylguanine 

Relevant articles and documents

Direct Prebiotic Pathway to DNA Nucleosides

It is assumed that RNA played a key role in the origin of life, and the transition to more complex but more stable DNA for continuous information storage and replication requires the development of a ribonucleotide reductase to obtain the deoxyribonucleot

High-yield regioselective synthesis of 9-glycosyl guanine nucleosides and analogues via coupling with 2-N-acetyl-6-O-diphenylcarbamoylguanine

-

New 7-methylguanine derivatives targeting the influenza polymerase PB2 cap-binding domain

The heterotrimeric influenza virus polymerase performs replication and transcription of viral RNA in the nucleus of infected cells. Transcription by "cap-snatching" requires that host-cell pre-mRNAs are bound via their 5′ cap to the PB2 subunit. Thus, the PB2 cap-binding site is potentially a good target for new antiviral drugs that will directly inhibit viral replication. Docking studies using the structure of the PB2 cap-binding domain suggested that 7-alkylguanine derivatives substituted at position N-9 and N-2 could be good candidates. Four series of 7,9-di- and 2,7,9-trialkyl guanine derivatives were synthesized and evaluated by an AlphaScreen assay in competition with a biotinylated cap analogue. Three synthesized compounds display potent in vitro activity with IC50 values lower than 10 μM. High-resolution X-ray structures of three inhibitors in complex with the H5N1 PB2 cap-binding domain confirmed the binding mode and provide detailed information for further compound optimization.